EURADIA Newsletter

Winter 2016


An internal review has been undertaken to assess the impact of the original DIAMAP project and report published 2010. EURADIA and its members are currently assessing the progress made on the research road maps. Under the lead of the chair, Professor Chantal Mathieu (KU Leuven, Belgium), the DIAMAP project manager Natalie van den Briel sought collaboration with the contributors to DIAMAP 1 to assist in this work. The outcomes will be used by EURADIA in its advocacy strategy at the European Institutions. In addition, an online survey was circulated to assess how different stakeholders used DIAMAP to identify areas for improvement. This information will allow EURADIA to evaluate the project’s use and create inputs for further project development and improvement. Thank you to everyone who took part in the survey - your contribution is much appreciated.   

European  Diabetes Working Group (EUDWG) Meeting

Diabetes: The Unmet Needs. Key Priorities for European Diabetes Research

LOW Private Salons, European Parliament, Strasbourg
3 February 2016

EURADIA is currently acting as secretariat for the ECD, and we organised a meeting on 3 February 2016 in the European Parliament, Strasbourg, which focused on diabetes research. The meeting was hosted by the EU Diabetes Working Group (EUDWG) of MEPs, a cross-party, cross-national, informal working-group of MEPs, supported by the European Coalition for Diabetes (ECD). The principle aim of the EUDWG is to improve both prevention of diabetes, as well as the health and quality of life of European citizens living with diabetes, through European Union (EU) policy. Within the European Parliament the aim is to create awareness of the disease in order to push for political actions on prevention and to improve early detection and therapy.

For the EU to be a leader in prevention and treatment we need to invest in research - also at European level. (Pictured left to right: Christel Schaldemose MEP, Prof Michael Stumvoll, EURADIA Chair, Commissioner Carlos Moedas Research and Innovation, Mr Chris Delicata, ECD Chair.) The keynote speakers at this meeting were Prof Stefano del Prato and Commissioner Carlos Moedas, DG Research and Innovation. The Commissioner was very supportive of the work of the EUDWG. 
The meeting included short presentations from the host MEPs, the ECD co-Chairs, a number of MEPs, and presentations from speakers Commissioner Moedas and Professor Stefano del Prato, University of Pisa, Italy and Chairman, European Foundation for the Study of Diabetes. The meeting report will be available shortly on the ECD website
CHRODIS: The EU Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life-Cycle
EURADIA participates in JA-CHRODIS through its membership in ECD. The importance of this project is that diabetes is the only named disease. This requires participation in CHRODIS meetings, particularly those dealing with the development of National Diabetes Plans. Partners from the JA-CHRODIS work on type 2 diabetes have produced a policy brief on National Diabetes Plans, together with the WHO Europe’s European Observatory on Health Systems and Policies. 
Find out more about the CHRODIS project here

InterConnect FP7 Initiative
Global Data for Diabetes and Obesity Research
Pre-EASD Non-Commercial Symposium
Monday 14 September 2015, Stockholm

The FP7-funded InterConnect project ( aims to change the way that data are used in population research into the causes of diabetes and obesity. EURADIA is specifically responsible in its work package for developing a sustainable and dynamic network of stakeholders and we will also be disseminating information about InterConnect to the research community, funders, stakeholders and the wider public. The InterConnect team held a well-attended, interactive Symposium on Global Data for Diabetes and Obesity Research immediately before the 2015 EASD Annual Meeting in Stockholm. This Symposium engaged scientists, research funders and stakeholders in a new approach to optimising the use of existing data that is secure, scalable and sustainable within a simple governance framework.  It included how InterConnect is:
  • Enhancing discovery of data via a searchable study registry
  • Optimising data for re-use via harmonisation and new toolkits
  • Creating a network for federated meta-analysis across cohorts where the data stays at source and the analysis comes to the data.

DALI FP7 Project
Diabetes and Pregnancy Vitamin D and Lifestyle Intervention for Gestational Diabetes Mellitus Prevention

Final Outcomes Meeting
Thursday 10 December 2015, Brussels

The FP7-funded DALI project is the framework for 13 partners from 11 countries to cooperate in a Europe-wide and large-scale study with the aim to develop effective preventive measures for Gestational Diabetes Mellitus. The final DALI meeting explored the final outcomes of the Project. The meeting brought together key European stakeholders in this interactive forum, which presented the main findings and results of the DALI project. Interactive workshop discussion generated recommendations on screening and prevention for pregnant women. In addition, expert speakers discussed issues such as transgenerational transmission of diabesity risk and its prevention in pregnancy.


DZD Diabetes Research School 2016 in Munich: Save the date!
The 4th DZD Diabetes Research School will take place in Munich on September 11-12, 2016 immediately before the EASD Annual Meeting. The German Center for Diabetes Research (DZD) is inviting young scientists to discuss current questions of diabetes research with Michael Czech (USA), Francesco Beguinot (Italy), Ruth E. Gimeno (USA), Andrew Hattersley (UK) at this outstanding event. Keep informed: Twitter: @DiabResearch

ESPE 2015
ESPE enjoyed a very successful annual conference in Barcelona, with research presented at ESPE 2015 receiving significant attention from the world’s media. During the week of the conference, items from the meeting were reported in over 860 individual news stories in 26 different languages. Press releases circulated by the ESPE office generated particular interest in three studies: • Asthma medications during infancy linked to stunted growth (Antti Saari, Kuopio, Finland) • Discovery of an association between height and cancer (Emelie Benyi, Stockholm, Sweden) • Creation of insulin-producing cells that may treat diabetes (Philippe Lysy, Brussels, Belgium)
21st FEND Annual Conference, 9-10 Sept 2016 Munich

The Call for Abstracts can be found shortly at Registration will open in March.

Youth Leadership Camp 2016

IDF Europe will be organizing the 6th edition of its Youth Leadership Camp (YLC) in the summer of 2016 in collaboration with one of its Members. The venue will be chosen from applications submitted by IDF European Members. Please request a camp venue application form from Lala Rabemananjara at Relevant information on the organization of the YLC can be found here  The previous editions of the IDF Europe Youth Leadership Camp took place in Slovenia, Italy, Croatia and the Netherlands. IDF Europe is looking to organise the 2016 edition of the Camp in a different European country.

Encapsulated stem cells halt type 1 diabetes in mice for six months

Dr Doug Melton, working on a project led by Dr Daniel Anderson and Dr Robert Langer at Massachusetts Institute of Technology, has in January shown encapsulated human islet (insulin-producing) cells transplanted into mice can withstand the autoimmune attack in type 1 diabetes, effectively halting the condition for up to six months. The findings, reported in Nature Medicine and Nature Biotechnology detailed results from ongoing studies to develop an encapsulated islet cell therapy for treatment of type 1 diabetes. Sarah Johnson, UK Director of Policy and Communication at JDRF said: “We are really pleased our continued support of Dr Melton’s research is showing these results and an early indication that encapsulation could be a new method of treating type 1 diabetes in the future…It’s significant to see a study of this length return such promising results. If this study can be replicated in humans then one day we could potentially free people with type 1 diabetes from a life of insulin injections.” More here

14th International Primary Care Diabetes Europe Conference

More information about the 2016 PCDE Conference is available here

New Cutting-Edge Website for Diabetes Launched by AstraZeneca - EVOLVE for Diabetes

Expert Views, Opinions, and Lectures to AdVance Education (EVOLVE) for Diabetes ( is AstraZeneca’s new non-promotional, educational website for healthcare professionals (non-US) and the scientific community. It provides comprehensive and state-of-the-art scientific materials, in the form of highly interactive and engaging resources and tools on all aspects of diabetes. Content for the website has been developed by globally renowned diabetes experts and topics covered on the website include: 
  • What have Recent CV Outcomes Trials Taught Us? - Professor Peter Grant, UK        
  • Macrovascular Complications - Dr James R Gavin III, US
  • Microvascular Complications - Dr Mark Kennedy, Australia
  • Targeting Inflammation in the Treatment of Diabetes - Dr Jan Ehses, Canada
  • T2DM: Epidemiological Trends in Today's World - Professor Kamlesh Khunti, UK
In addition to interactive resources and tools, the website also contains the latest news in diabetes as well as coverage from key international diabetes congresses, with reporting done by diabetes experts. Please visit for further information. 

European Parliament votes to reject high sugar levels in baby food

In January the European Parliament voted to reject draft EU rules on baby food, which would have allowed baby foods to contain high levels of sugar and products to be labelled for use from 4 months of age. The European Commission must now bring the regulations into line with the sugar recommendations from the World Health Organisation and the World Health Assembly's requirement that baby foods are not marketed for use before 6 months of age. More here.

DG Health and Food Safety

A new Framework for Action on Mental Health and Wellbeing

The EU Joint Action on Mental Health and Wellbeing was launched in 2013 to champion mental health as a European public health priority and to develop tools to support Member States in improving conditions for the prevention, diagnosis and care of mental disorders in their countries. The Final Conference of the Joint Action, held in Brussels on 21-22 January 2016, presented the opportunity to discuss progress made over the past three years and to hold a debate on the Framework for Action on Mental Health and Wellbeing, the most important outcome of this initiative. Find out more here.

DG Research and Innovation

EC considers setting up a new European Innovation Council 

The European Commission on February 17 launched a Call for Ideas on the setting up of a European Innovation Council to support Europe's most promising innovators. The Call for Ideas seeks proposals from all interested parties, including innovators who do not usually participate in EU support schemes, on how a European Innovation Council could be designed to improve Europe's capacity to generate and scale up breakthrough innovations. Carlos Moedas, Commissioner for Research, Science and Innovation, said: "Europe has excellent science, but we lack disruptive market-creating innovation. This is what is needed to turn our best ideas into innovative products and services that provide growth and jobs. I want to test the idea of creating a European Innovation Council, which could replicate for entrepreneurs what the European Research Council is doing for Europe's best researchers”. Find out more here

The Personalised Medicine Conference, June 1-2

This conference in Brussels will explore personalised medicine through a research policy lens. Europe is a leader in personalised medicine, an interdisciplinary field which will drive the health research and innovation agenda for years to come with a view to improving healthcare. The conference aims to showcase the current state of the art in the area and explore future research and innovation challenges. It will also introduce a new collaboration among health research funding and policy making organisations called the International Consortium for Personalised Medicine (IC PerMed). 
Registration will open end February here. 


Question: Reducing VAT on fruit and vegetables at EU level and encouraging people to eat a balanced diet
Date: 12 January 2016
MEP: Frédérique Ries (ALDE)

Question: Preventing strokes and encouraging healthy living
Date: 5 November 2015
MEP: Patrizia Toia (S&D)
Answer given by Mr Andriukaitis on behalf of the Commission

Question: Ban on junk food advertising
Date: 3 November 2015
MEP: Miriam Dalli (S&D)
Answer given by Mr Andriukaitis on behalf of the Commission

Question: Link between artificial sweeteners and metabolic disorders
Date: 30 October 2015
MEP: Bart Staes (Verts/ALE)
Answer given by Mr Andriukaitis on behalf of the Commission

Lilly's new Fellowship Awards Program will foster post-doctoral career development through the selection of highly innovative research proposals. Program benefits includes but not limited to full post-doctoral salary and benefits for up to four years. Only UK and US based fellows are eligible to apply. More here.


Raising Awareness of Regulatory Requirements : A guidance tool for researchers
EFPIA and IMI have prepared a guidance document  to raise awareness of the various opportunities to interact with regulators in the framework of research on regulatory sciences with a potential impact on public health. This succinct guidance tool provides a high-level overview of the existing services offered by regulators and is intended for use by researchers who wish to have a better understanding of these opportunities. Note that this document does not replace official procedures and requirements to validate or obtain formal advice from the relevant regulatory agencies. 

Childhood obesity is an important health challenge for almost all countries in the European Region. The statistics are disturbing, with rising rates of overweight and obesity reported in many European countries in recent years. The World Health Assembly recently adopted a global target for all countries to renew their efforts to halt the rise in overweight among children under 5 by 2025. In the European Region, Member States have done much to find and implement solutions, with positive developments in some policy areas. Halting the rise in childhood obesity, however, requires stronger and decisive action. The report of the WHO Commission on Ending Childhood Obesity, launched on 25 January, encapsulates an important package of comprehensive and integrated recommendations that will inspire and foster even more action at the European level. 

If you are in the process of putting together a consortium or seeking research partners, please do let us know and we will include your project details both here in our newsletter and on the EURADIA website. Please send a message to


EFGCP Annual Conference 2016
Faster and Safer Paths to New Treatments with Medicines and Medical Devices
1 & 2 March 2016,
Brussels, Belgium

Recommendations and controversies in clinical nutrition (RECONUT)
4-6 March 2016
Bangkok, Thailand

21-23 April, 2016
Dubrovnik, Croatia

29-30 April, 2016
Barcelona, Spain

6-8 May, 2016
Kualar Lumpur, Malaysia

Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
May 19-21 2016
Shangai, China

DG Research and Innovation
1-2 June 2016
Brussels, Belgium

21– 23 June 2016
Budapest, Hungary

30 June - 2 July, 2016.
Bratislava, Slovakia

9-10 Sept 2016
Munich, Germany

EASD 2016
12-16 September 
Munich, Germany

Send us your news

EURADIA publishes meeting and deadline dates on its website (under News – Diary Dates) and will include relevant reports and articles in its newsletter.  Contact

EURADIA: The Alliance for European Diabetes Research

EURADIA is an alliance of non-profit organisations and health care companies working together to further the cause of diabetes research. EURADIA has existed since 2003 and as a registered non-profit organisation in Germany since 2007. EURADIA UK was registered as an independent charity in 2013. 

EURADIA serves as a visible and effective advocate for diabetes research at the highest levels, representing the best interests of both academia and the healthcare industry. 


Copyright ©  2016 EURADIA All rights reserved


Non-Profit-Association, registered at the County Court Düsseldorf. Registry Number: VR 9885
Registered in England and Wales as a company limited by guarantee, registry number 8608154 and as registered charity number 1154726
unsubscribe from this list | update subscription preferences